Expected to provide up to 24% weight loss after 11 months, Retatrutide is administered once weekly, making it a convenient option for patients
MSTN: A KEY REGULATOR OF MUSCLE AND FAT MSTN, also known as growth/differentiation factor-8 (GDF-8), is a member of the transforming growth factor- (TGF-) superfamily that negatively regulates skeletal muscle mass.[12] Its regulatory role in muscle was first discovered through the observation of a doubled muscle phenotype in homozygous Mstn knockout ( Mstn / ) mice, with the increased muscle mass resulting from both hyperplasia and hypertrophy of muscle cells.[12,13] This phenotype is thought to arise because MSTN represses myoblast proliferation and differentiation.[12,14,15] Such a role of MSTN in muscle is well conserved across species, as a doubled muscle phenotype has been observed not only in Mstn / mice, but also in humans,[16] dogs,[17] sheep,[18] and cattle,[19] with naturally occurring mutations in the MSTN gene
Because the FDA has a responsibility to ensure that people are receiving safe, legitimate medications, its concerns about compounded semaglutide are valid
No FDA-approved oral tirzepatide exists as of April 2026